These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25039326)

  • 1. Access to medicines in developing countries: ethical demands and moral economy.
    Cassier M; Correa M
    Dev World Bioeth; 2014 Aug; 14(2):ii-viii. PubMed ID: 25039326
    [No Abstract]   [Full Text] [Related]  

  • 2. 'Pharmacy of the World' is ill?
    Goyal A
    Dev World Bioeth; 2015 Apr; 15(1):ii. PubMed ID: 25615937
    [No Abstract]   [Full Text] [Related]  

  • 3. Access to life-saving medicines and intellectual property rights: an ethical assessment.
    Schroeder D; Singer P
    Camb Q Healthc Ethics; 2011 Apr; 20(2):279-89. PubMed ID: 21435303
    [No Abstract]   [Full Text] [Related]  

  • 4. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to medicines and the rhetoric of responsibility.
    Barry C; Raworth K
    Ethics Int Aff; 2002; 16(2):57-70. PubMed ID: 15709279
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction: Access to life-saving medicines and intellectual property rights.
    Schroeder D
    Camb Q Healthc Ethics; 2011 Apr; 20(2):277-8. PubMed ID: 21435302
    [No Abstract]   [Full Text] [Related]  

  • 7. Why are generic drugs being held up in transit? Intellectual property rights, international trade, and the right to health in Brazil and beyond.
    Rosina MS; Shaver L
    J Law Med Ethics; 2012; 40(2):197-205. PubMed ID: 22789040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The responsibility of research universities to promote access to essential medicines.
    't Hoen EF
    Yale J Health Policy Law Ethics; 2003; 3(2):293-300. PubMed ID: 14577145
    [No Abstract]   [Full Text] [Related]  

  • 9. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
    Guennif S
    Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliminating neglected diseases in poor countries: a conversation with Andrew Witty. Interview by Susan Dentzer.
    Witty A
    Health Aff (Millwood); 2009; 28(3):w411-6. PubMed ID: 19299425
    [No Abstract]   [Full Text] [Related]  

  • 12. Patents and access to drugs in developing countries: an ethical analysis.
    Sterckx S
    Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patents and human rights: a heterodox analysis.
    Gold ER
    J Law Med Ethics; 2013; 41(1):185-98. PubMed ID: 23581665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global pharmaceutical development and access: critical issues of ethics and equity.
    Lage A
    MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 16. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction: Pharmaceutical firms and the right to health.
    de Campos TC; Pogge T
    J Law Med Ethics; 2012; 40(2):183-7. PubMed ID: 22789038
    [No Abstract]   [Full Text] [Related]  

  • 18. Access to essential drugs, human rights and global justice.
    Shalev C
    Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
    [No Abstract]   [Full Text] [Related]  

  • 19. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction: pharmaceutical innovation: law & the public's health.
    Outterson K
    J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.